股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海微创医疗机器人（集团）股份有限公司 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 6,599,543 | RMB | | | 1 RMB | | 6,599,543 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 6,599,543 | RMB | | | 1 RMB | | 6,599,543 | | 2. 股份分 ...

Summary of MicroPort Robotics Conference Call Company Overview - **Company**: MicroPort Robotics - **Industry**: Medical Robotics Key Financial Highlights - **Revenue**: In the first half of 2025, revenue reached RMB 176 million, a year-on-year increase of 77% [2][3][14] - **Overseas Revenue**: Contributed nearly 60% of total revenue, with a year-on-year growth of 189% [2][3][5] - **Net Loss**: Reduced by 59% year-on-year, from RMB 280 million to RMB 115 million [3][14] - **Free Cash Flow**: Net outflow improved by 43% year-on-year, amounting to RMB 135 million [2][3][14] - **Full Year Revenue Projection**: Expected to grow by 85% to RMB 480 million, with overseas revenue contributing approximately 55% [3][19] Product and Market Performance - **Global Orders**: Total global orders approached 150 units, with over 90 units for the TUMAI surgical robot and 60 units for the HONGHU orthopedic robot [2][3][5] - **Commercial Installations**: Over 100 units of all product lines have been commercially installed [2][3][5] - **Surgical Volume**: TUMAI achieved over 12,000 cumulative surgeries globally, with June 2025 alone seeing over 10,000 surgeries [2][4][11] - **International Certifications**: TUMAI received registrations in over 30 countries, including India and Australia [2][6][7] Technological Innovations - **Remote Surgery Robot**: TUMAI's remote surgery robot received approval from the Chinese FDA in April 2025, marking a significant milestone as the first registered remote surgical robot globally [2][3][12] - **Clinical Applications**: Successful implementation of remote surgeries in multiple regions, including Europe and the U.S. [12][30] Competitive Landscape - **Domestic Competition**: The domestic market is increasingly competitive, with some local brands engaging in price wars. MicroPort Robotics is focusing on maintaining quality and efficiency rather than initiating price cuts [17][25] - **International Strategy**: The company is leveraging its established global sales channels and management expertise to penetrate new markets, particularly in Southeast Asia and Latin America [21][34] Research and Development - **R&D Investment**: R&D expenses were RMB 88 million in the first half of 2025, a decrease of 46% year-on-year [16] - **Focus Areas**: Current R&D efforts are concentrated on expanding product specifications, enhancing performance, and improving cost efficiency [16] Future Outlook - **Market Expansion**: The company anticipates strong growth in overseas markets, with expectations to exceed 30 new orders in 2025 [18][35] - **Sustainability of Growth**: The focus will be on improving operational efficiency and responding to competitive pressures while maintaining a strong market position [36] Additional Insights - **Consumables Revenue**: Consumables now account for over 10% of total revenue, with expectations for continued growth [27][22] - **Regulatory Environment**: Potential pricing regulations from the National Healthcare Security Administration could impact pricing strategies, but the company is well-positioned to adapt [24][25][26] This summary encapsulates the key points from the conference call, highlighting the financial performance, product advancements, competitive strategies, and future outlook of MicroPort Robotics.

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 截至2025年6月30日止六個月之中期業績公告 董事會欣然公佈本集團截至2025年6月30日止六個月之未經審核綜合中期業績， 連同截至2024年6月30日止六個月之比較數字，已經審計委員會審閱。 於本公告內，「我們」及「我們的」指本公司及（倘文意另有所指）本集團。本公 告所載若干金額及百分比數據已因約整進行調整，或已約整至一個或兩個小 數位。任何表格、圖表或其他地方中總額與當中所列金額總和之間的任何差異 乃因約整所致。 | 財務摘要 | | | | | --- | --- | --- | --- | | | 截至6月30日止六個月 | | | | | 2025年 | 2024年 | 變動 | | | 人民 ...

（於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 於本公告日期，執行董事為何超博士、房聰女士及劉雨先生；非執行董事為孫洪斌先生及陳 琛先生；以及獨立非執行董事為李明華博士、姚海嵩先生及鍾偉文先生。 上海微創醫療機器人（集團）股份有限公司（「本公司」與其附屬公司合稱「本集 團」）董事（「董事」）會（「董事會」）茲通告，本公司謹定於2025年8月28日（星期四） 舉行董事會會議，以考慮及通過（其中包括）本集團截至2025年6月30日止六個 月的中期業績及公佈，並考慮派發中期股息（如有），以及處理其他事項。 承董事會命 上海微創醫療機器人（集團）股份有限公司 主席 孫洪斌先生 中國上海，2025年8月18日 董事會會議召開日期 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海微创医疗机器人（集团）股份有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 6,599,543 | RMB | | 1 | RMB | | 6,599,543 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 6,599,543 | RMB | | 1 | RMB | | 6,599,543 | | ...

Financial Performance - Revenue for 2024 reached RMB 257,249 thousand, a significant increase of 146% compared to RMB 104,592 thousand in 2023[9] - Gross profit for 2024 was RMB 86,220 thousand, up from RMB 14,694 thousand in 2023, reflecting a gross margin improvement[9] - The company reported a pre-tax loss of RMB 647,101 thousand for 2024, an improvement from a loss of RMB 1,023,530 thousand in 2023[9] - The total equity decreased to RMB 257,678 thousand in 2024 from RMB 501,755 thousand in 2023, reflecting a decline in shareholder value[10] - The company reported a 36.8% year-on-year reduction in net losses, laying a solid foundation for future growth and profitability[21] - The adjusted net loss for the year ended December 31, 2024, was RMB 482.6 million, a decrease from RMB 869.1 million in 2023, indicating a significant improvement in financial performance[90] - The free cash flow net outflow decreased by 42%, from RMB 670 million to RMB 388 million, indicating improved cash flow management[21] Assets and Liabilities - Total assets decreased to RMB 1,279,039 thousand in 2024 from RMB 1,427,907 thousand in 2023, indicating a reduction in asset base[10] - Non-current assets fell to RMB 422,493 thousand in 2024, down from RMB 633,859 thousand in 2023, highlighting a significant decline[10] - Total liabilities increased to RMB 1,021,361 thousand in 2024 from RMB 926,152 thousand in 2023, indicating rising financial obligations[10] - The asset-liability ratio increased to 80% as of December 31, 2024, compared to 65% in 2023, reflecting a higher level of debt relative to assets[102] Market Expansion and Product Development - The company is focusing on expanding its global market presence and enhancing commercialization efforts for its surgical robot products[15] - The company aims to innovate and provide comprehensive robotic surgical solutions to meet the growing demands in minimally invasive surgery[11] - The total global orders for the company's multi-track product portfolio exceeded 100 units by the end of 2024, with 39 new signed orders for the TuMai surgical robot and over 60 cumulative commercial orders[16] - TuMai's market share in China increased, with 19 new installations during the reporting period, and over 60% of installations in top-tier hospitals[16] - The company achieved 11 commercial installations and sales in overseas markets in 2024, with the Honghu robot completing nearly 2,000 clinical surgeries across over 70 medical institutions globally[18] - The company plans to continue optimizing operational efficiency and enhancing innovation capabilities to reshape the global medical technology landscape[22] Certifications and Regulatory Approvals - The company received CE certification for the TuMai robot in May 2024, marking a significant milestone in its global expansion efforts, with certifications obtained in nearly 20 countries[17] - TUMAI received EU CE certification (MDR) in May 2024, applicable for various surgical procedures, enhancing its international market competitiveness with nearly 20 certifications across different countries[33] - The single-port laparoscopic robot received NMPA registration approval in February 2025, diversifying the product portfolio and improving market competitiveness[33] - HONGHU has obtained market approvals from nearly ten regulatory authorities, including NMPA, FDA, and EU CE, achieving full coverage in developed and key emerging markets[33] Research and Development - The company has applied for a total of 1,333 patents globally, with 509 granted, including 338 in China and 171 overseas, covering advanced fields such as clinical applications and AI technology[74] - The company has two R&D centers in Shanghai and Shenzhen, focusing on clinical needs and promoting product upgrades through multi-center clinical trials[69] - The product pipeline includes multiple robotic surgery products across five major categories, with several in rapid industrialization stages[36] - The company is investing $50 million in R&D for new technologies aimed at enhancing user experience and operational efficiency[5] Training and Support - The company has conducted over 1,600 training sessions for its surgical robots, with more than 2,000 participants, including over 160 overseas doctors from over 40 countries[70] - The company has developed a mobile training platform for its surgical robots, addressing the shortage of training resources in China and accelerating the accessibility of robotic surgery[71] - The company plans to establish more surgical robot training centers to enhance communication with doctors and patients, aiming to accelerate the adoption of surgical robots[76] Strategic Initiatives - The company aims to leverage its collaboration with the Micro-Invasive Medical Group to enhance its overseas sales network and expand its product offerings[18] - The company plans to utilize a total of HKD 266.31 million from the fundraising proceeds by December 31, 2024[115] - The company has committed HKD 34.22 million for continuous product enhancement and optimization, with HKD 26.4 million remaining to be used by the end of 2025[111] - The company has launched the "third-generation remote surgery" initiative, integrating satellite technology for comprehensive global coverage of remote surgeries[66] Environmental and Social Responsibility - The company is committed to environmental responsibility, focusing on creating a sustainable business without compromising environmental integrity[146] - The environmental, social, and governance report provides a comprehensive review of the company's environmental policies and performance for the 2024 fiscal year[147] Shareholder and Management Information - The board plans to review and determine the compensation for directors and senior management based on performance and market comparisons, ensuring alignment with company strategy[98] - The company has adopted share incentive and stock option plans as rewards for directors, supervisors, and eligible employees[168] - The management emphasizes the importance of operational efficiency and strategic development in driving future growth[121]

Summary of Conference Call Company and Industry Overview - The conference call discusses the advancements and financial performance of **Mikron Robotics**, a domestic surgical robot manufacturer, focusing on its innovative products and market expansion efforts in both domestic and international markets [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44]. Key Points and Arguments Product Innovations and Market Expansion - **Mikron Robotics** has achieved significant breakthroughs in the domestic orthopedic surgical robot market, establishing a presence in high-end markets in the US and Europe, with nearly 2,000 clinical surgeries performed globally [1]. - The company has received regulatory approvals in major markets including India, Japan, the UK, and Canada, achieving a total of nine global certifications, making it the first and only domestic surgical robot to gain product registration across five continents [2]. - The **Tupai Robot** has pioneered ultra-remote surgical technology, utilizing various communication methods, and has conducted over 300 remote surgeries across multiple departments [2][3]. Financial Performance - In 2024, **Mikron Robotics** reported a revenue of **257 million RMB**, reflecting a strong growth trend driven by both domestic and international market expansion [7]. - The adjusted net loss decreased significantly from **1.02 billion RMB** in 2023 to **640 million RMB** in 2024, a reduction of nearly 45% [8]. - Free cash flow outflow decreased by 42% from **670 million RMB** in 2023 to **380 million RMB** in 2024, indicating improved cash management [8][14]. Future Projections - The company anticipates continued revenue growth in 2025, projecting an increase of over 85%, reaching approximately **480 million RMB** due to strong performance in both domestic and international markets [10][11]. - The operational expenses are expected to decrease by about 10% in 2025, with a target of keeping them below **520 million RMB** [12]. Competitive Landscape - The company is confident in its competitive position against established players like the **Da Vinci Robot**, emphasizing its ability to innovate rapidly and meet local market needs [29][33]. - The domestic market for surgical robots is expected to grow significantly due to supportive government policies and the increasing adoption of domestic products [16][17][18]. Challenges and Considerations - The company acknowledges the challenges posed by the longer sales cycles in the medical equipment sector, particularly in overseas markets, which may affect revenue distribution throughout the year [11]. - The impact of tariffs on business operations is minimal, as the company has a robust supply chain and production capabilities [32]. Conclusion - **Mikron Robotics** is positioned for significant growth in the surgical robot market, with a strong focus on innovation, market expansion, and improving financial metrics. The company is optimistic about its future prospects, driven by increasing demand for surgical robots and supportive government policies [43][44].

Financial Performance - For the year ended December 31, 2024, the company reported revenue of RMB 257.2 million, a year-on-year increase of 146.0% compared to RMB 104.6 million in 2023[5]. - Gross profit for the same period was RMB 86.2 million, representing a significant increase of 486.8% from RMB 14.7 million in the previous year[5]. - The company recorded a pre-tax loss of RMB 647.1 million, a reduction of 36.8% from a loss of RMB 1,023.5 million in 2023[5]. - Adjusted net loss for the year was RMB 482.6 million, down 44.5% from RMB 869.1 million in the prior year[5]. - Basic and diluted loss per share improved to RMB 0.66 from RMB 1.06, reflecting a decrease of 37.7%[5]. - The company reported a net loss attributable to equity shareholders of RMB 642.4 million, down from RMB 1,012.2 million in the previous year, indicating improved financial performance[6]. - The company incurred a pre-tax loss of RMB 3,168,000 for 2024, a decrease from a loss of RMB 13,342,000 in 2023, showing an improvement of 76.3%[23]. - The company recorded a net loss of RMB 647.1 million for the year ending December 31, 2024, compared to a net loss of RMB 1,023.5 million in 2023, resulting in an adjusted net loss of RMB 482.6 million[105]. Revenue Growth - Total revenue for 2024 reached RMB 257,249,000, a significant increase from RMB 104,592,000 in 2023, representing a growth of 146.1%[18]. - Revenue from medical devices and accessories sales amounted to RMB 252,410,000, with service income contributing RMB 2,230,000[18]. - The total expected revenue from existing customer contracts as of December 31, 2024, is RMB 19,128,000, up from RMB 6,144,000 in 2023, indicating a growth of 211.5%[19]. - Revenue from external customers in China was RMB 153,725,000 in 2024, compared to RMB 83,385,000 in 2023, reflecting an increase of 84.1%[22]. - The geographical revenue breakdown shows that revenue from Europe increased to RMB 36,076,000 in 2024 from RMB 7,503,000 in 2023, a growth of 380.5%[22]. Cost Management - The company achieved a 42% reduction in free cash flow outflow, decreasing from RMB 670 million in 2023 to RMB 388 million in 2024[6]. - Sales and marketing expenses decreased by 12.8% to RMB 207.9 million for the year ended December 31, 2024, down from RMB 238.4 million for the year ended December 31, 2023, due to adjustments in sales strategy[96]. - Administrative expenses decreased by 56.3% to RMB 55.3 million for the year ended December 31, 2024, compared to RMB 126.4 million for the year ended December 31, 2023, primarily due to operational efficiency improvements[97]. - R&D expenses decreased by 45.8% from RMB 569.2 million for the year ended December 31, 2023, to RMB 308.7 million for the year ending December 31, 2024, due to a focus on products nearing commercialization and improved R&D efficiency[98]. - Total employee costs for the year ending December 31, 2024, were RMB 178.9 million, down from RMB 350.4 million in 2023, primarily due to a reduction in workforce[99]. Cash Flow and Liquidity - The company’s cash and cash equivalents increased to RMB 612.2 million in 2024 from RMB 507.7 million in 2023, reflecting better liquidity management[10]. - Free cash flow net outflow decreased by 42%, from RMB 670 million to RMB 388 million, indicating improved cash flow management[57]. - Cash and cash equivalents increased from RMB 507.7 million as of December 31, 2023, to RMB 612.2 million as of December 31, 2024, primarily due to H-share placement and effective debt financing[112]. Strategic Initiatives - The company continues to focus on sustainable business growth and operational efficiency, enhancing its competitive advantage in the industry through a multi-track layout and superior product performance[47]. - The company is leveraging advancements in core technologies and integration with new technologies like 5G and artificial intelligence to enhance its product offerings and expand into international markets[44]. - The company has established two R&D centers in Shanghai and Shenzhen, focusing on rapid response to clinical needs and promoting industry upgrades[84]. - The company plans to increase its marketing budget by 15% to enhance brand visibility and customer engagement[146]. - The company aims to continue its global strategy by building an innovative platform for medical robots and collaborating with top hospitals and research institutions[92]. Product Development and Innovation - The company has applied for a total of 1,333 patents globally, with 509 granted, including 338 in China and 171 overseas, enhancing its innovation capabilities[89]. - The R-ONE vascular interventional robot has been approved by NMPA and has successfully entered the Chinese market with two commercial installations[50]. - The company has established the largest remote surgery network globally, completing over 300 remote surgeries with a 100% success rate[53]. - The company is developing a "third-generation remote surgery" concept, integrating satellite technology for comprehensive global coverage[82]. - The company has successfully completed over 300 cases of 5G remote clinical surgeries globally, achieving a 100% success rate and setting 25 world records[66]. Market Expansion - The company is exploring potential acquisitions to strengthen its market position and expand its technological capabilities[145]. - The expansion into the European market is a key focus, with projected sales growth of 40% in that region over the next two years[145]. - The company has successfully navigated regulatory approvals, including certifications from ANVISA and NMPA, facilitating entry into new markets[144]. Corporate Governance - The company has complied with all applicable corporate governance codes and regulations during the reporting period[130]. - There were no significant investments, acquisitions, or disposals of subsidiaries, associates, or joint ventures during the reporting period[136]. - The company does not recommend the distribution of a final dividend for the reporting period[140].

Financial Performance - Revenue for the first half of 2024 reached RMB 99,237,000, a significant increase from RMB 47,603,000 in the same period of 2023, representing a growth of 108.5%[13] - Gross profit for the first half of 2024 was RMB 47,013,000, compared to RMB 22,068,000 in the first half of 2023, indicating a growth of 112.6%[13] - The company reported a pre-tax loss of RMB 279,950,000 for the first half of 2024, an improvement from a loss of RMB 544,733,000 in the same period of 2023[13] - The company recorded revenue of RMB 992 million, a significant increase of 108.5% year-on-year, driven by strong sales momentum in both domestic and overseas markets[18] - The net loss narrowed by 48.6% year-on-year, with free cash flow net outflow decreasing by 49.7% to RMB 235.3 million, indicating improved cash flow management[20] - The company achieved a 48.6% reduction in net losses year-on-year, laying a solid foundation for future growth and profitability[31] - The company reported a total comprehensive loss of RMB 280,020,000 for the period, compared to RMB 541,530,000 in 2023, a reduction of 48.3%[126] - The company’s total liabilities increased to RMB 394,510 thousand as of June 30, 2024, compared to RMB 240,876 thousand as of December 31, 2023, indicating a rise of 63.6%[129] Assets and Liabilities - Total assets decreased to RMB 1,122,886,000 as of June 30, 2024, down from RMB 1,427,907,000 at the end of 2023, reflecting a decline of 21.4%[14] - Non-current assets were RMB 579,666,000 as of June 30, 2024, compared to RMB 633,859,000 at the end of 2023, a decrease of 8.5%[14] - Cash and cash equivalents decreased from RMB 507.7 million as of December 31, 2023, to RMB 221.1 million as of June 30, 2024, mainly due to early-stage commercialization and ongoing R&D activities[77] - The company's current asset net value was RMB 72.6 million as of June 30, 2024, down from RMB 108.8 million as of December 31, 2023, primarily due to ongoing expenditures in R&D and commercialization activities[82] - The company's inventory as of June 30, 2024, was RMB 243.4 million, with most inventory deemed suitable for sale[74] - The company's net asset value decreased to RMB 257,734 thousand as of June 30, 2024, down from RMB 501,755 thousand as of December 31, 2023, a decline of 48.7%[129] Product Development and Market Expansion - The company has developed multiple products across five major surgical robot categories, including laparoscopic, orthopedic, vascular, natural orifice, and percutaneous procedures[16] - Three flagship products, namely TUMAI, Dragonfly Eye, and Honghu, have received market approval through expedited pathways[16] - The company aims to establish a global medical robot solution innovation platform, focusing on extending and reshaping life through robotic surgical solutions[16] - The core product, TUMAI, has been commercialized in 20 hospitals across China, maintaining the largest market share in the domestic laparoscopic surgical robot market[18] - The flagship product, Honghu, has expanded its overseas sales footprint to over 20 countries across five continents, contributing to revenue growth in regions like Europe and Australia[19] - The R-ONE vascular intervention robot has quickly accumulated several intent orders since its approval in December 2023, marking a significant step in market expansion[18] - The company is building the largest remote surgery network globally, with over 30 TUMAI systems connected for remote operations, facilitating international collaboration and product promotion[22] - The company aims to enhance product competitiveness and market coverage, focusing on sustainable revenue growth in both domestic and international markets[22] Research and Development - The company has established nearly 40 clinical application and training centers for TUMAI and 20 for Honghu, training over 200 lead surgeons and conducting over 1,000 training sessions[21] - The company has applied for a total of 1,314 patents globally, with 459 patents granted, including 304 in China and 155 overseas, covering advanced fields such as clinical applications and AI technology[53] - The company is focused on developing five core underlying technologies for surgical robots, ensuring continuous innovation and product development capabilities[48] - The company is actively pursuing new product development and technological advancements in the medical robotics field[173] Operational Efficiency and Cost Management - The management emphasized a commitment to cost reduction and efficiency improvement while maintaining strategic focus for sustainable development[17] - Sales and marketing expenses decreased by 27.3% to RMB 922 million for the six months ended June 30, 2024, due to adjustments in commercialization strategy and optimization of marketing team resources[61] - Administrative expenses fell by 61.2% to RMB 301 million for the six months ended June 30, 2024, primarily due to operational efficiency improvements and a streamlined management team[62] - R&D costs decreased by 47.3% to RMB 1,641 million for the six months ended June 30, 2024, as the company focused on optimizing the performance of commercialized products[63] Corporate Governance and Shareholder Information - The company aims to enhance its corporate governance practices to ensure compliance with applicable codes[109] - The share incentive plan allows for a maximum of 95,199,428 H shares to be awarded, representing approximately 9.93% of the company's issued share capital as of the report date[103] - The company did not grant any rights to directors or supervisors to acquire shares or bonds during the six months ending June 30, 2024[95] - The company has confirmed compliance with the standard code for securities trading by all directors and supervisors during the reporting period[98] Future Outlook - The company expects to continue as a going concern for at least the next twelve months, supported by market expansion plans and strict operational cost control[137] - The company has set ambitious performance guidance for the upcoming fiscal year, anticipating significant revenue growth[172] - The company is exploring potential mergers and acquisitions to accelerate growth and market expansion[173]

Financial Performance - For the six months ended June 30, 2024, the company reported revenue of RMB 99.2 million, a significant increase of 108.7% compared to RMB 47.6 million for the same period in 2023[2]. - Gross profit for the same period was RMB 47.0 million, up 112.6% from RMB 22.1 million year-on-year[2]. - The company recorded a net loss of RMB 280.0 million, a reduction of 48.7% from a net loss of RMB 544.7 million in the previous year[3]. - Basic and diluted loss per share improved to RMB 0.29 from RMB 0.56, reflecting a 48.2% decrease in loss per share[4]. - The company achieved a significant reduction in operating expenses, leading to a decrease in operating loss to RMB 244.6 million from RMB 519.3 million[4]. - Free cash flow outflow was RMB 235.3 million, a 49.7% decrease compared to the previous year, primarily due to increased revenue and cost reduction strategies[3]. - For the six months ended June 30, 2024, the company reported a net loss of RMB 279,950,000, compared to a net loss of RMB 539,012,000 for the same period in 2023[10]. - The company generated operating cash outflow of RMB 206,309,000 for the six months ended June 30, 2024[10]. - The company incurred a total interest expense of RMB 9,834,000 for the six months ended June 30, 2024, compared to RMB 8,623,000 for the same period in 2023[15]. - The company recognized an impairment loss of RMB 15,697,000 on equity-accounted investees for the six months ended June 30, 2024[16]. - The company reported a basic loss per share of RMB 0.29 for the six months ended June 30, 2024[18]. - The company recorded a net loss of RMB 104 million from financial instruments measured at fair value for the six months ended June 30, 2024, compared to a net loss of RMB 19 million in the same period last year[74]. - Adjusted net loss for the six months ended June 30, 2024, was RMB 2,184 million, an improvement from RMB 4,717 million in the same period of 2023[79]. Market Expansion and Sales Growth - The company successfully expanded its overseas commercialization, achieving sales growth in the US, Europe, and Australia, with sales volume doubling compared to the previous year[3]. - The company’s revenue from the Chinese market was RMB 63,763,000 for the six months ended June 30, 2024, up from RMB 38,580,000 in the same period of 2023[13]. - The company has established a strong international presence, with sales in Europe and Australia doubling compared to the previous year, and over 300 TKA surgeries completed in more than ten medical institutions in the US and Europe[34]. - The company has seen a 5.4% year-on-year increase in medical equipment exports in 2023, with a 54.8% increase compared to 2019, indicating growing global recognition of Chinese high-end medical equipment[29]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by the end of 2025[107]. Product Development and Innovation - The core product, TUMAI, achieved commercial installation in 20 hospitals across China, maintaining the leading market share in domestic laparoscopic surgical robots, with over 1,300 clinical surgeries completed[33]. - The company has received NMPA approval for the R-ONE vascular interventional robot, which is accelerating its promotion in hospitals and has already secured multiple sales orders[33]. - The product pipeline includes multiple robotic surgical products across five major categories, with several in advanced stages of development[38]. - The company is focusing R&D resources on commercialized products, including Tumai and Honghu, to provide innovative robotic surgical solutions more rapidly[38]. - The company has successfully completed nearly 200 remote clinical surgeries globally using its surgical robots, achieving a 100% success rate and setting over 20 national and global first records[35]. - The company has established nearly 40 clinical application and training centers globally, with over 100 surgeons certified during the reporting period[44]. - The company’s innovative products are now applicable to nearly 200 types of indications, covering multiple departments and diverse surgical procedures[45]. - The company has applied for a total of 1,314 patents globally, with 459 granted, including 304 in China and 155 overseas, covering advanced fields such as clinical applications and AI technology[62]. - The company has added 64 new authorized patents in the first half of 2024, including 23 overseas invention patents, enhancing its core technology's international presence[62]. Cost Management and Operational Efficiency - The company has implemented cost reduction and efficiency enhancement strategies, optimizing production processes and improving market competitiveness[36]. - Sales and marketing expenses decreased by 27.3% to RMB 922 million for the six months ended June 30, 2024, due to adjustments in commercialization strategies and optimized resource allocation[69]. - Administrative expenses fell by 61.2% to RMB 301 million for the six months ended June 30, 2024, primarily due to operational efficiency improvements and a reduction in management team size[70]. - R&D costs decreased by 47.3% to RMB 1,641 million for the six months ended June 30, 2024, as the company focused on optimizing the performance of commercialized products[71]. - The company is focusing on optimizing production processes and improving operational efficiency, which has effectively enhanced cost control and cash flow management[32]. Corporate Governance and Compliance - The company aims to enhance corporate governance practices to protect shareholder interests[95]. - The interim financial report for the six months ending June 30, 2024, was reviewed by KPMG according to the relevant standards[96]. - The audit committee, consisting of three members, reviewed and discussed the interim results for the six months ending June 30, 2024[97]. - The company has adopted a standard code for securities transactions by directors and supervisors, confirming compliance during the reporting period[95]. - The company revised its articles of association to reflect changes in Chinese regulations and the new Company Law effective July 1, 2024[101]. Future Outlook - The company projects a revenue growth of 20% for the next fiscal year, aiming for RMB 1.8 billion in total revenue[107]. - The company anticipates sustainable growth in the surgical robot market due to increasing recognition of robotic advantages, improved healthcare infrastructure, and government support for innovative medical devices[63]. - The company plans to explore potential acquisitions to strengthen its product portfolio and market position[107]. - The company has allocated RMB 200 million for research and development in the upcoming year, focusing on innovative surgical solutions[109].